In recent years, immunotherapy, cell therapy, and gene therapy have taken center stage as new approaches for eliminating malignant tumors. TSA, also called neoantigens, are somatic mutations present in individual cancers, and are truly foreign proteins expressed only on cancer cells (TSAs are not found on normal healthy tissues). Emerging evidence suggests ideal and successful cancer immunotherapies which target neoantigens, combined with immune checkpoint inhibition therapy, achieve greater therapeutic effects.
One of the major challenges with personalized neoantigen therapeutic vaccines, however, has been that the current neoantigen prediction algorithms require further optimization, as current neoepitope prediction methods result in low rates of validation. In fact, studies show less than 3% accuracy rate (~2%) of neopeptide CD8+ T cell stimulation.
A technology that overcomes this lack of accuracy is a polymer nanoshell delivery mechanism developed and patented by Taiwan’s Academia Sinica (the national research institute of Taiwan, originally founded in Nanking in 1928 as the national research institute of China). The combinatorial PLGA-based polymer nanoshell encapsulates the peptide antigen of interest, reducing reactogenic adverse effects and triggering precise multivalent immune potentiation, resulting in a yield of nearly 30% accuracy rate (>29%) in CD8+ T cell stimulation. The high potency and safety profile of the vaccine renders it capable of minimizing vaccination regimen and duration in improving treatment outcome.
The first neoantigen cancer vaccines to be on ABC Treatment Access Platform targets Colorectal Carcinoma. ABC believes that both a personalized cancer vaccine and a neoantigen-based therapeutic plan are around the corner in the future of oncology medicine.
*Note: For complete description of therapeutics and diagnostics with citations, please refer to ABC ICO Prospectus